首页> 外文期刊>Arthritis research & therapy. >Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice
【24h】

Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, prevents the development of murine systemic lupus erythematosus-like diseases in MRL/lpr autoimmune mice and BDF1 hybrid mice

机译:Y27,一种4-羟基喹啉-3-甲酰胺的新型衍生物,可预防MRL / lpr自身免疫小鼠和BDF1杂交小鼠中鼠类系统性红斑狼疮样疾病的发展

获取原文
获取原文并翻译 | 示例
       

摘要

Introduction: Naturally occurring CD4+CD25+regulatory T (Treg) cells are central to the maintenance of peripheral tolerance. Impaired activity and/or a lower frequency of these cells lead to systemic lupus erythematosus (SLE). Manipulating the number or activity of Treg cells is to be a promising strategy in treating it and other autoimmune diseases. We have examined the effects of Y27, a novel derivative of 4-hydroxyquinoline-3-formamide, on SLE-like symptoms in MRL/lpr autoimmune mice and BDF1 hybrid mice. Whether the beneficial effect of Y27 involves modulation of CD4+CD25+Treg cells has also been investigated.Methods: Female MRL/lpr mice that spontaneously develop lupus were treated orally by gavage with Y27 for 10 weeks, starting at 10 weeks of age. BDF1 mice developed a chronic graft-versus-host disease (GVHD) by two weekly intravenous injections of parental female DBA/2 splenic lymphocytes, characterized by immunocomplex-mediated glomerulonephritis resembling SLE. Y27 was administered to chronic GVHD mice for 12 weeks. Nephritic symptoms were monitored and the percentage of CD4+CD25+FoxP3+Treg peripheral blood leukocyte was detected with mouse regulatory T cell staining kit by flowcytometry. Purified CD4+CD25+Tregs were assessed for immune suppressive activity using the mixed lymphocyte reaction.Results: The life-span of MRL/lpr mice treated with Y27 for 10 weeks was significantly prolonged, proteinuria and renal lesion severity were ameliorated, and blood urea nitrogen, triglyceride and serum anti-double-stranded DNA antibodies were decreased. Similar results were found in chronic GVHD mice. Administration of Y27 had little impact on percentage of the peripheral blood lymphocyte CD4+CD25+Foxp3+Treg cells in both groups of mice. In contrast, the suppressive capacity of CD4+CD25+Treg cells in splenocytes was markedly augmented in Y27-treated mice ex vivo.Conclusions: Experimental evidence of the protect effects of Y27 against autoimmune nephritis has been shown. The mechanism may involve enhancement of the suppressive capacity of CD4+CD25+Treg cells.
机译:简介:自然产生的CD4 + CD25 +调节性T细胞(Treg)对维持外周耐受性至关重要。这些细胞的活动受损和/或频率降低会导致系统性红斑狼疮(SLE)。操纵Treg细胞的数量或活性将成为治疗Treg和其他自身免疫性疾病的一种有前途的策略。我们已经检查了Y27,4-羟基喹啉-3-甲酰胺的新型衍生物,对MRL / lpr自身免疫小鼠和BDF1杂交小鼠中SLE样症状的影响。方法:从10周龄开始,用Y27灌胃对自发性狼疮的雌性MRL / lpr小鼠进行口服治疗10周,以研究Y27的有益作用是否涉及CD4 + CD25 + Treg细胞的调节。 BDF1小鼠通过每周两次静脉注射母体雌性DBA / 2脾淋巴细胞而发展为慢性移植物抗宿主病(GVHD),其特征是类似于SLE的免疫复合物介导的肾小球肾炎。将Y27施用于慢性GVHD小鼠12周。监测肾病症状并通过流式细胞术用小鼠调节性T细胞染色试剂盒检测CD4 + CD25 + FoxP3 + Treg外周血白细胞的百分比。结果:经Y27处理10周的MRL / lpr小鼠的寿命显着延长,蛋白尿和肾损害的严重程度得到改善,血尿素水平得到了改善。氮,甘油三酸酯和血清抗双链DNA抗体降低。在慢性GVHD小鼠中发现了相似的结果。施用Y27对两组小鼠外周血淋巴细胞CD4 + CD25 + Foxp3 + Treg细胞的百分比影响很小。相比之下,Y27处理的小鼠离体的脾细胞中CD4 + CD25 + Treg细胞的抑制能力显着增强。结论:显示了Y27对自身免疫性肾炎的保护作用的实验证据。该机制可能涉及增强CD4 + CD25 + Treg细胞的抑制能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号